The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.
Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.